Acceleration Robotics Launch ROBOTCORE™ to Speed-up ROS 2 Robots
Acceleration Robotics S.L., a robotics semiconductor startup based in the Basque Country and focused on designing customized brains for robots to hasten their response time via FPGAs and GPUs released ROBOTCORE ™, a hardware acceleration framework for the Robot Operating System (ROS), the standard in robotics. Delivering semiconductor building blocks for robots, the company creates custom compute architectures for high performance robots through hardware acceleration while remaining robot and accelerator-agnostic (supporting popular FPGAs and GPUs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005050/en/
ROBOTCORE™ helps build faster compute architectures for robots, or robot cores, that makes robots faster, more deterministic and power-efficient. It provides a development experience for creating robot hardware accelerators similar to the standard ROS development flow. (Photo: Acceleration Robotics)
ROBOTCORE™ allows robotic engineers to create ROS and ROS 2 API-compatible Intellectual Property (IP) cores that increase the robot's performance, including latency and throughput. These “ robot cores” make robots faster, more deterministic and power-efficient. ROBOTCORE™ launches with support for more than 10 development boards, including the most popular hardware acceleration solutions to build robots with ROS.
The framework builds on top of proven open-source software in robotics, such as ROS 2, so that roboticists don't spend time redeveloping what already works and focus instead on delivering higher performance robotic applications. While providing a vendor-agnostic ROS-centric development flow, ROBOTCORE™ solves customer design challenges in robotic areas including sensing, perception, mapping, localization, motion control, low-level control or actuation, with speedups surpassing 500x modern processors.
“Robots are networks of networks, with sensors passing data to compute technologies and actuators. These networks can be understood as the nervous system of the robot. Like with the human nervous system, low latency and real-time information is fundamental for the robot to behave coherently. Faster robots (or with more dexterity) require faster computations. Hardware acceleration with ROBOTCORE™ empowers exactly this. With ROS being the common language roboticists use to build “robot brains”, ROBOTCORE™ extends ROS and deals with GPU and FPGA vendor-proprietary libraries, empowering hardware acceleration across silicon vendors”. – Víctor Mayoral-Vilches, Acceleration Robotics, Founder.
Additional resources
- ROBOTCORE ™ performance benchmarks
- Sign up for Hardware Acceleration News in Robotics
- Join the ROS 2 Hardware Acceleration Working Group
About Acceleration Robotics
Acceleration Robotics is a firm focused on designing customized brains for robots to hasten their response time. Founded by top robotic experts to deliver semiconductor building blocks for robots, the company leverages GPUs and FPGAs to create custom hardware that speeds up a robot's operation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005050/en/
Contact information
Víctor Mayoral-Vilches
(+34) 616151561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 08:00:00 EET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom